Background/Aims: Newly identified IL-10-producing regulatory B cells (Bregs) have been shown to play an important role in the suppression of immune responses. Chronic immune activation participates in the pathogenesis of dilated cardiomyopathy (DCM) but whether Bregs are involved in its development remains unclear. We aimed to investigate the circulating frequency and function of Bregs in DCM. Methods: In total, 35 DCM patients (20 men and 15 women) and 44 healthy controls (23 men and 21 women) were included in the experiment, and the frequency of Bregs was detected using flow cytometry. Results: According to our results, the frequency of circulating IL-10-producing Bregs was significantly lower in DCM patients compared with healthy controls. Furthermore, the CD24 hi CD27 + B cell subset in which IL-10-producing Bregs were mainly enriched from DCM patients showed impaired IL-10 expression and a decreased ability to suppress the TNF-α production of CD4 + CD25 -Tconv cells and to maintain Tregs differentiation. Correlation analysis showed that the frequency of IL-10-producing Bregs and the suppressive function of CD24 hi CD27 + B cells were positively correlated with left ventricular ejection fraction and negatively correlated with NT-proBNP in DCM patients. Conclusions: In conclusion, the reduced frequency and impaired functions suggest a potential role of Bregs in the development of DCM.
Introduction
Dilated cardiomyopathy (DCM) is one of the most common causes of heart failure, which is characterized by ventricular enlargement and progressive deterioration of systolic function [1, 2] . Although the pathogenesis of DCM is complicated, there is increasing evidence that autoimmune disorders with cellular and humoral immune activation are involved in the development of DCM [3, 4] . In DCM patients, T cells display enhanced expression of activation surface markers, including CD25, CD69, HLA-DR and CD40 ligand [5, 6] . Additionally, auto-antibodies directed against heart specific-antigens were detected in their serum [7, 8] . However, regulatory T cells (Tregs) have a beneficial role in DCM by suppressing TH1-dominant CD4 + T-cell responses [9] [10] [11] . B cells accelerate DCM development by secreting antibodies against cardiac proteins [12, 13] . In addition to their functions in antibody secretion, antigen presentation and cytokine and chemokine production, B cells exhibit regulatory capacity in several human diseases, such as experimental autoimmune encephalomyelitis (EAE) [14] , diabetes [15] and collagen-induced arthritis (CIA) [16] . The discrete subpopulation of B cells that has regulatory capacity is termed regulatory B cells (Bregs) . Although the existence of Bregs has been well documented, there is no specific transcription factor or membrane marker to distinguish them from other B cells [17] . To date, IL-10 production has been considered a defining trait of Bregs [18] . The phenotypes of human Bregs remain controversial, and different B cell subsets, including CD19 + CD24
hi CD38 hi and CD19 + CD24 hi CD27 + B cells, produce IL-10 and exhibit regulatory functions in different diseases [19, 20] .
Here, we prospectively studied the frequency, phenotype and regulatory functions of Bregs in DCM patients. According to our results, the frequency of IL-10-producing Bregs was decreased in DCM patients. Consistent with previous studies, IL-10-producing Bregs were mainly enriched in CD24 
Materials and Methods
Patients 35 DCM patients and 44 healthy controls were included in the experiments to evaluate IL-10 production and identify B cell subsets. DCM diagnosis was based on the guidelines of the World Health Organization (WHO) [21] . Left ventricular enlargement with LVEDD > 5.5 cm and LVEF < 45%, which were estimated by echocardiography, were the inclusion criteria for DCM. Exclusion criteria included hypertensive heart disease, valvular heart disease, coronary heart disease, diabetes, other autoimmune diseases, serious infection, pregnancy, endocrine disease, tumors, or receiving immunosuppressive agents. The investigation conforms to the principles outlined in the Declaration of Helsinki (2013) of the World Medical Association, and the trial was approved by the Ethics Committee of Tongji Medical College of Huazhong University of Science and Technology. Patients and healthy controls were all Chinese Han population and recruited after obtaining written, informed consent.
Sample preparation and cell isolation
Blood samples were obtained after permission was received. After centrifugation, serum was collected, aliquoted, and frozen at -80°C for NT-proBNP measurements. PBMCs were separated by Ficoll density gradient centrifugation and quantified by hemocytometer before subsequent use. CD19 + B cells were isolated from PBMCs by magnetic bead purification (Miltenyi Biotec, BergischGladbach, Germany) followed by staining with the fluorescence surface marker anti-human CD24-FITC (BioLegend, San Diego, CA, USA) and anti-human CD27-Percp-Cy5.5 (BioLegend, San Diego, CA, USA) for 30 min at 4°C. Subsequently, the CD24 hi CD27
+ B cells were obtained by fluorescence-activated cell sorting using the FACSAria cell-sorting system (BD Biosciences, San Jose, CA, USA). 
Flow cytometry analysis
To characterize IL-10 + B cells, PBMCs were stimulated with CpG-ODN 2006 (2.5 ug/ml; Invitrogen, Carlsbad, CA, USA) and CD40L (1 ug/ml; R&D Systems, Minneapolis, MN, USA) for 48 hours, and PMA (50 ng/ml; Sigma-Aldrich, St. Louis, MO, USA), ionomycin (250 ng/ml; Sigma-Aldrich, St. Louis, MO, USA) and brefeldin A (1 ul/test; BD Biosciences, San Jose, CA, USA) were added for the last 5 hours. Surface marker anti-human CD19-APC, CD24-FITC, CD27-PerCP/Cy5.5 and CD38-PE/Cy7 mAbs were stained at 4°C for 30 min, and then the cells were fixed, permeabilized and stained to detect intracellular cytokines with an antihuman IL-10-PE mAb.
In a co-culture system, anti-human CD4-FITC, CD25-PE, and CD127-PE/Cy7 mAbs were used to identify Tregs. To evaluate the cytokine production of Tconv cells, anti-human TNF-α-APC combined with CD4-FITC were used in the staining method described above.
All of the fluorescent antibodies described above were purchased from BioLegend (San Diego, CA, USA). Isotype controls were used for background correction and to confirm antibody specificity. Stained cells were analyzed with a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA).
T cell proliferation and suppression assays
For the T cell proliferation and suppression assays, CD4 +
CD25
-Tconv cells were cultured either alone or 1:1 with sorted CD24 hi CD27 + B cells. Cells were resuspended at a concentration of 10 5 per 100 µl and cultured in a final volume of 200 µl in U-bottom 96-well plates. Cells were incubated in RPMI-1640 medium (Gibco, Life Technologies, Grand Island, NY, USA) with 10% heat-inactivated FCS (Gibco, Life Technologies, Grand Island, NY, USA), 100 U/ml penicillin, 100 U/ml streptomycin, 25 mM HEPES, and 2 mM L-glutamine at 37°C.
To detect the TNF-α production of CD4 + CD25 -Tconv cells, the cells were stimulated with plate-bound anti-CD3 (1 ug/ml; eBioscience, San Diego, CA, USA) and soluble anti-CD28 (1 ug/ml; eBioscience, San Diego, CA, USA) for 3 days. PMA (50 ng/ml; Sigma-Aldrich, St. Louis., MO, USA), ionomycin (250 ng/ml; Sigma-Aldrich, St. Louis, MO, USA), and brefeldin A (1 ul/test; BD Biosciences, San Jose, CA, USA) were added for the last 5 hours of culture. The supernatants were collected for ELISA (R&D Systems, Minneapolis, MN, USA) detection, and the cells were harvested for flow cytometry (BD Biosciences, San Jose, CA, USA) analysis.
For the proliferation assay, CD4 + CD25 -Tconv cells were stained with CFSE (1 uM; eBioscience, San Diego, CA, USA) ahead of the culture. The staining procedure of CFSE was performed according to the manufacturer's instructions. After, the cells were cultured in the presence of plate-bound anti-CD3 (1 ug/ ml; eBioscience, San Diego, CA, USA) and soluble anti-CD28 (1 ug/ml; eBioscience, San Diego, CA, USA) for 4 days. After being harvested, the CFSE of CD4 + CD25
-Tconv cells was analyzed by flow cytometry (BD Biosciences, San Jose, CA, USA) to evaluate their proliferation.
To explore the capacity of CD24 hi CD27 + B cells to maintain Tregs, the cells were cultured in the presence of plate-bound anti-CD3 (0.5 ug/ml; eBioscience, San Diego, CA, USA). After 3 days of culture, the cells were collected and assayed by flow cytometry (BD Biosciences, San Jose, CA, USA).
Electrochemiluminescence immunoassay of serum NT-proBNP
Roche Elecsys Electrochemiluminescence Immunoassay (Roche Diagnostics, Indianapolis, IN, USA) was used to detect serum NT-proBNP, and the protocol was performed according to the manufacturer's instructions.
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Results
Basic Patient Characteristics
The basic characteristics of healthy controls and DCM patients are presented in Table 1 . Compared to healthy controls, patients with DCM showed a significant reduced left ventricular ejection fraction (LVEF), enlarged left ventricular enddiastolic dimension (LVEDD) and elevated NT-proBNP concentration. There were no differences in gender and age between the 2 groups.
The proportion of Bregs was decreased in patients with DCM
Bregs have no specific surface marker or transcription factor, and IL-10 production is considered their defining characteristic. To compare the circulating frequency of Bregs, we collected peripheral blood of 35 DCM patients and 44 healthy controls. After stimulation with CD40L and CpG for 48 h, PBMCs were used for intracellular IL-10 staining. The proportions of CD19 + B cells were 8.12% ± 0.55% in healthy controls and 6.88 ± 0.51% in DCM patients, and the difference was not significant (P = 0.10). However, patients with DCM were associated with a significant impairment in the frequency of Bregs (P < 0.01) compared to healthy controls ( Fig. 1) . [22] [23] [24] [25] . To determine in which commonly recognized B cell subsets Bregs from DCM patients were enriched, we stained the PBMCs with CD19, CD24, CD38 and CD27. Consistent with previous studies, IL-10-producing Bregs were mainly within the CD24 hi CD27
+ B cells in both groups. The proportion of IL-10-producing Bregs in CD24 hi CD27 + B cells were 66.29% ± 1.87% in patients and 66.95% ± 1.45% in controls ( Fig. 2A and 2B ), which indicated that there is no significant difference between the 2 groups (P = 0.78). Moreover, IL-10-producing Bregs possessed comparable proportions in CD24 hi CD38
hi B cells and CD24 int CD38 int B cells between DCM patients and healthy controls (data not shown).
To determine which subset was responsible for the decreasing frequency of IL-10-producing Bregs, we investigated IL-10 expression of both B cell subsets in healthy controls and DCM patients. We were surprised to find that IL-10 expression of CD24 hi CD27 + B in DCM patients was significantly lower than in healthy donors (21.54% ± 1.42% vs. 27.36% ± 1.00%, Fig. 2C and 2D) . + B cells from both groups suppressed IFN-γ production by T cells, but there is no significant difference of inhibition ability between DCM patients and Healthy controls, which means the inhibition ability of CD24 hi CD27 + B cells from DCM patients in IFN-γ production by T cells is not impaired (Fig. 3) . 
CD24 hi CD27 + B cells in DCM patients showed unimpaired ability to inhibit Tconv proliferation
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Bregs correlated with cardiac function in DCM patients
To discover the relationship between Bregs and cardiac function, we performed a correlation analysis. Our results showed that the frequency of IL-10-producing Bregs and the suppressive function of CD24 hi CD27
+ B cells on TNF-α production of Tconv cells were positively correlated with LVEF while they were negatively correlated with NT-proBNP in DCM patients (Fig. 6) . The data suggested that defective Bregs in DCM was correlated with the severity of heart failure. 
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Discussion
The immune system is activated during the progress of DCM [3, 4] . Previously, Tregs were thought to be the vital suppressor to maintain homeostasis. However, a newly identified B cell subpopulation called Bregs were shown to inhibit inflammation [28] . There is no specific surface marker or transcription factor of Bregs, and IL-10 production is considered to be the sole identification trait [17] . During the last decade, human Bregs were studied by many research groups and confirmed to be dysfunctional in many autoimmune diseases, such as systemic lupus erythematosus (SLE), immune thrombocytopenia (ITP) and chronic graft-versus-host disease (cGVHD) [19, [29] [30] [31] [32] . In this study, we found that the frequency of circulating IL-10-producing Bregs was significantly lower in DCM patients compared to healthy controls. Consistent with previous studies, IL-10-producing Bregs were mainly enriched in CD24 IL-10 remains the best phenotypic marker for human Bregs. B cells from freshly collected PBMCs express little IL-10 and after stimulation with PMA, ionomycin and brefeldin A for 5h, the frequency of IL-10 in B cells increases approximately 0.6% [20] . We detected the IL-10 expression of PBMCs stimulated through this method and consistent with previous studies, healthy controls and patients showed minimal IL-10 expression (0.7% and 0.9%) after a 5-h stimulation (data not shown). Furthermore, the difference between the 2 groups was not statistically significant. However, a study by Guo et al. demonstrated a different result. 30 healthy controls and 30 DCM patients were involved in their experiment, and they showed an increase in the frequency of IL-10-producing Bregs from DCM patients compared to healthy controls (5.2% ± 2.6% vs. 2.3% ± 0.9%) [33] , with a much higher proportion of IL-10-producing B cells compared with our results and previous studies. The discrepancy may be attributed to different patients and methods of stimulation between the two studies. The DCM patients and healthy controls included in their study were relatively younger. Additionally, whole blood was incubated for 5 h in their experiment while we used PBMCs instead.
The minimal IL-10 expression of freshly isolated blood B cells makes quantitative analysis between the 2 groups difficult. However, after in vitro stimulation for 48 h, B cells can be further induced to express cytoplasmic IL-10 [20] . CD40L and CpG-ODN2006 are optimal inducers of IL-10 production. In healthy controls, the frequency of IL-10 + B cells was significantly increased to approximately 5% after culture in the presence of CD40 and CpG-ODN2006 for 2 days [20] . According to previous studies, IL-10 expression levels significantly changed in many autoimmune diseases, such as SLE, RA and MS, after a 48-h stimulation [20] . Thus, we further stimulated PBMCs through this method and found that fewer IL-10-producing Bregs were detected in DCM patients. This finding suggested that the potential capacity of B cells to produce IL-10 was impaired in DCM patients compared to controls, which might partly contribute to the excessive activation of the immune response in DCM.
As with Bregs, there may be various distinct subsets of human Bregs. We focused on the two novel phenotypes, namely CD24 hi CD38
hi B cells and CD24 hi CD27 + B cells, which were widely reported to have regulatory effects [19, 20, 27, 34] . Consistent with previous studies, we found that Bregs were predominantly identified within the CD24 hi CD27
+ B cell subpopulation. Although there was no difference in the ratios of both subsets between the 2 groups, IL-10 expression was significantly lower in CD24 + B cells. During the development of DCM, persistent and chronic autoimmune T cell responses to cardiac self-antigen and elevated pro-inflammatory cytokines mediate continual cardiac destruction [26, [35] [36] [37] [38] . Previous studies have shown that Bregs exhibit their suppressive functions via IL-10, TGF-β and cell to cell contact involving CD86 and CD80 in both mouse and humans [19, 39] . Consistent with previous studies, we found that CD24 + B cells to inhibit the proliferation and IFN-γ production of Tconv was not compromised in DCM patients, which suggested that other mechanisms besides IL-10 might participate in the processes.
Tregs are decreased and have impaired functionality in DCM [26, 40] . Additionally, cardiac-specific auto-antibodies that have been reported in DCM patients showed a pathogenic role in cardiac dilatation and dysfunction. Tregs could directly suppress B cell immunoglobulin production independent of T helper cells [41] . Bregs function by skewing T cell differentiation toward a regulatory phenotype in both mice [42, 43] and humans [18, 19, 27] 
Conclusion
This research illustrated a decreased frequency of circulating IL-10-producing Bregs in DCM patients. Moreover, IL-10 production was specifically decreased in CD24 
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